Most Recent Articles by Mario Sznol, MD
VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.
Mario Sznol, MD, of the Yale University School of Medicine in New Haven, Connecticut, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.
Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.
Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.
Mario Sznol, MD, comments on the results of his phase 1 study reporting on data from patients with metastatic melanoma treated with nivolumab.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC
- Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma
- Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia
- Pediatric CML: Life-Long Considerations With TKI Therapy
- Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia
- Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL
- Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations
- Can Oncolytic Viruses Improve Immunotherapies?
- Cognitive Behavioral Therapy Compared With Acupuncture for Insomnia in Cancer Survivors
- CYCORE System May Improve Radiotherapy-Associated Symptoms in Head and Neck Cancer